TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

Chau Dang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.